Phenotypes associated with this allele

• Allele Symbol: Csnk1a1⁺
• Allele Name: wild type
• Allele ID: MGI:2439921
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Csnk1a1^tm1.1Ybn/Csnk1a1^+ Tg(Vil1-cre/ERT2)23Syr/0 Trp53^tm1Brn/Trp53^tm1Brn	involves: 129 * C57BL/6 * CD-1 * DBA/2	MGI:5543694
cn2	Crbn^tm1.1Ble/Crbn^tm1.1Ble Csnk1a1^tm1.1Ybn/Csnk1a1^+ Tg(Mx1-cre)1Cgn/?	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:6280334
cn3	Csnk1a1^tm1c(KOMP)Wtsi/Csnk1a1^+ Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * C57BL/6N * CBA	MGI:5762598

Genotype
MGI:5543694

cn1

• Allelic Composition: Csnk1a1^tm1.1Ybn/Csnk1a1⁺; Tg(Vil1-cre/ERT2)23Syr/0; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129 * C57BL/6 * CD-1 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased carcinoma incidence ( J:204886 )

• within 6 months, 7 of 9 tamoxifen-treated mice develop invasive carcinomas that permeates the bowel muscular wall into the subserosal fat with some involvement of the serosal surface (stage T4)

Genotype
MGI:6280334

cn2

• Allelic Composition: Crbn^tm1.1Ble/Crbn^tm1.1Ble; Csnk1a1^tm1.1Ybn/Csnk1a1⁺; Tg(Mx1-cre)1Cgn/?
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

homeostasis/metabolism

increased physiological sensitivity to xenobiotic ( J:267091 )

• hematopoietic stem and progenitor cells are more sensitive to lenalidomide in culture than cells from Csnk1a1^tm1.1Ybn/+ Tg(Mx1-cre)1Cgn mice

Genotype
MGI:5762598

cn3

• Allelic Composition: Csnk1a1^{tm1c(KOMP)Wtsi}/Csnk1a1⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * C57BL/6N * CBA
• Cell Lines: EPD0270_3_B02

mortality/aging

premature death ( J:216977 )

• survival of polyinosinic-polycytidylic acid [poly(I:C)] treated mice is impaired

hematopoietic system

abnormal hematopoietic system morphology/development ( J:216977 )

• lethally irradiated wild-type mice transplanted with mutant whole bone marrow cells show full reconstitution of the bone marrow, normal hemoglobin, elevated white blood cell counts with lymphocytosis, and bone marrow with mildly dysplastic hypolobulated micro-megakaryoctyes in atypical locations 8 weeks after poly(I:C) induction and mice develop elevated platelet count over time

decreased common myeloid progenitor cell number ( J:216977 )

• 15 months after poly(I:C) treatment, mice show a near-complete loss of myeloid progenitor cells

decreased bone marrow cell number ( J:216977 )

• 8 weeks after poly(I:C) treatment, a reduction in bone marrow cellularity and in the percentage of long-term (LT; Lin^lowSca-1+ckit+CD150+CD48-) and short-term (ST; Lin^lowSca-1+ckit+CD150-CD48-) hematopoietic stem cells is seen

abnormal megakaryocyte morphology ( J:216977 )

• hypolobulated micro-megakaryocytes are seen 8 weeks after poly(I:C) induction

• whole bone marrow cells cultured in vitro in the presence of thrombopoietin show that CD41+ megakaryocytes shift toward hypoploidy

decreased myeloid cell number ( J:216977 )

• reduction of the myeloid lineage 15 months after poly(I:C) induction

decreased hematopoietic stem cell number ( J:216977 )

• 8 weeks after poly(I:C) treatment, a reduction in the percentage of long-term (LT; Lin^lowSca-1+ckit+CD150+CD48-) and short-term (ST; Lin^lowSca-1+ckit+CD150-CD48-) hematopoietic stem cells is seen 15 months after poly(I:C) treatment, mice show a decrease in the LT-HSCs and ST-HSCs

pancytopenia ( J:216977 )

• 15 months after poly(I:C) treatment, mice develop pancytopenia

abnormal erythroid lineage cell morphology ( J:216977 )

• reduction of the erythroid lineage 15 months after poly(I:C) induction